A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 316
- Registration Number
- NCT04083976
- Locations
- 🇧🇪
CHU UCL Namur - Site Dinant, Dinant, Belgium
🇧🇪UZA, Edegem, Belgium
🇧🇪AZ Maria Middelares, Gent, Belgium
A Study of JNJ-61393215 in the Treatment of Depression
- Conditions
- Major Depressive Disorder With Anxious Distress
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 222
- Registration Number
- NCT04080752
- Locations
- 🇺🇦
MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association, Glevakha, Ukraine
🇺🇸Collaborative NeuroScience Network, Garden Grove, California, United States
🇺🇸Atlanta Institute, Alpharetta, Georgia, United States
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 701
- Registration Number
- NCT04077463
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸UCSF Helen Diller Comprehensive, San Francisco, California, United States
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT04075396
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
🇪🇸Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain
A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Other: RSV Mobile ApplicationDrug: PlaceboDrug: JNJ-53718678 2.5 mg/kgDrug: JNJ-53718678 3 mg/kgDrug: JNJ-53718678 4.5 mg/kg
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT04068792
- Locations
- 🇦🇷
Instituto de Maternidad y Ginecología Nuestra Senora de las Mercedes, Tucumán, Argentina
🇧🇪UZ Antwerpen, Edegem, Belgium
🇵🇦Cevaxin 24 de diciembre, Panama, Panama
A Study of Paliperidone Palmitate 6-Month Formulation
- Conditions
- Schizophrenia
- Interventions
- Drug: PP6M injection Dose 1Drug: PP6M injection Dose 2
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 178
- Registration Number
- NCT04072575
- Locations
- 🇷🇺
Sverdlovsk Regional Clinical Psychiatric Hospital, Ekaterinburg, Russian Federation
🇦🇷Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales, Ciudad Autónoma De Buenos Aires, Argentina
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04060888
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, China
🇨🇳Anhui Province Hospital, Hefei, China
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT04042376
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, China
🇨🇳The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04033458
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1064
- Registration Number
- NCT04033445
- Locations
- 🇺🇸
Om Research LLC, Lancaster, California, United States
🇺🇸Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
🇺🇸Florida Research Network, LLC, Gainesville, Florida, United States